Vectus Biosystems progresses its human trials with lead cardiovascular drug candidate VB0004

Vectus Biosystems (ASX: VBS) non-executive director Maurie Stang joins Small Caps to discuss the company’s development of its lead cardiovascular drug VB0004.

A phase 1a human safety trial was successfully completed in Melbourne in September and demonstrated an impressive safety record.

The antifibrotic and antihypertension oral drug will move to the next phase of 1b testing and the company also plans to evaluate its impact in COVID-19 induced fibrotic damage.

Articles:
https://smallcaps.com.au/vectus-biosystems-phase-1b-drug-trial-treat-fibrosis-hypertension/
https://smallcaps.com.au/vectus-biosystems-unveils-more-promising-results-phase-1-clinical-trial/

For more information on Vectus Biosystems:
https://smallcaps.com.au/stocks/VBS/

-----------------------

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

-----------------------

WEBSITE
https://smallcaps.com.au/

PODCAST
https://smallcaps.com.au/podcast/

SOCIAL MEDIA
Facebook: https://www.facebook.com/SmallCapsASX
Twitter: https://twitter.com/SmallCapsASX
LinkedIn: https://www.linkedin.com/company/small-caps/

NEWSLETTER
https://smallcaps.com.au/subscribe/